DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
G• T••••••••• I••
Drug Discovery & Developmentgroup grade Aoff every schedule since Jun 30, 2024sponsor unattributed
Nothing material in the last 200 days. Last change: 30 Jun 2024, $32.4M principal held by 1 lender; matures Nov 2026.
Mark path, consensus per quarter end
100¢ · 101¢ · 102¢ · 102¢ · 102¢Q2 2023 to Q2 2024
Principal held
at least $32.4M
sum of BDC pieces, a lower bound
Fair value
$34.0M
102c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Nov 1, 2026
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2024
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2024, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $32.4M | 102¢ | 0 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, M••••••• D••• N••••••• 2026, P•••• + 5.65%, F•••• rate 9.15%, 6.75% E••• F | $32.4M | $34.0M 102c | S+565 bp |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2024
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Jun 30, 2024 | at least $32.4M | 102c | S+565 bp | Nov 1, 2026 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2024 | 1 | $32.4M | $34.0M | 102c | 0 |
| Mar 31, 2024 | 1 | $32.4M | $33.8M | 102c | 0 |
| Dec 31, 2023 | 1 | $77.5M | $80.8M | 102c | 0 |
| Sep 30, 2023 | 1 | $38.8M | $40.0M | 101c | 0 |
All 7 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2023 | 1 | $38.8M | $39.5M | 100c | 0 |
| Mar 31, 2023 | 1 | $58.1M | $58.8M | 100c | 0 |
| Dec 31, 2022 | 1 | $58.1M | $58.4M | 100c | 0 |
What changed
- Facility left every BDC scheduleJun 30, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- G• T•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it